U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07093385) titled 'Intravitreal Faricimab in Patients With Refractory Macular Edema' on July 12.
Brief Summary: This prospective study will include about 40 patients with resistant wet age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion edema (RVO) edema.The inclusion criteria are that all patients must be 40 years old or older, diagnosed with active wet AMD or macular edema due to RVO or DME, and have received at least four previous monthly injections of anti-VEGF other than faricimab. All patients will be switched to receive four loading doses of intravitreal faricimab (6 mg) at 4-week intervals for four m...